John Vanderzyl, MD
Family Medicine · Sugar Land, TXNPI 1396848990
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 897 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 13.0% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 897 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Abbott$2K
- Lilly USA, LLC$1K
- Amgen$1K
- Boehringer Ingelheim$1K
- AbbVie$983
- plus $10K from 54 others
Across 1,757 payments — averaging $2131.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$1.6M
- Novo Nordisk AS$1.1M
- Pfizer$948K
- Novartis$99K
- Gilead$24K
- Alnylam Pharmaceuticals Inc.$22K
- plus $13K from 1 others
What the payments were for
- Food & beverage$18,850100%
- Education$190%
- Gifts$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,880 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 111 | $119,105 |
| JanuviaSitagliptin Phosphate | 46 | $48,908 |
| EliquisApixaban | 50 | $47,184 |
| MounjaroTirzepatide | 38 | $47,025 |
| ProliaDenosumab | 17 | $28,357 |
| JardianceEmpagliflozin | 24 | $26,665 |
| FarxigaDapagliflozin Propanediol | 15 | $20,660 |
| VascepaIcosapent Ethyl | 18 | $16,328 |
| MyrbetriqMirabegron | 18 | $15,784 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 59 | $13,186 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $12,926 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $10,437 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 29 | $9,301 |
| Levothyroxine Sodium | 635 | $9,278 |
| Atorvastatin Calcium | 632 | $6,809 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $2,458 | $119,105111 claims |
| MerckJanuvia | $286 | $48,90846 claims |
| PfizerEliquis | $520 | $47,18450 claims |
| Lilly USA, LLCMounjaro | $1,245 | $47,02538 claims |
| AmgenProlia | $1,138 | $28,35717 claims |
| Boehringer IngelheimJardiance | $1,018 | $26,66524 claims |
| GSKShingrix, Arexvy | $748 | $22,48788 claims |
| AstraZenecaFarxiga | $912 | $20,66015 claims |
| Astellas Pharma US IncMyrbetriq | $287 | $15,78418 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $181 | $9,278635 claims |
| AbbVieSynthroid | $983 | $4,68181 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Sugar Land
- Anne Marie Ponce de LeonSugar Land$109K
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.